<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Adv Ther</journal-id><journal-id journal-id-type="iso-abbrev">Adv Ther</journal-id><journal-title-group><journal-title>Advances in Therapy</journal-title></journal-title-group><issn pub-type="ppub">0741-238X</issn><issn pub-type="epub">1865-8652</issn><publisher><publisher-name>Springer Healthcare</publisher-name><publisher-loc>Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25712918</article-id><article-id pub-id-type="pmc">4349943</article-id><article-id pub-id-type="publisher-id">186</article-id><article-id pub-id-type="doi">10.1007/s12325-015-0186-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Erratum</subject></subj-group></article-categories><title-group><article-title>Erratum to: The Fixed-Dose Combination of Olmesartan/Amlodipine Was Superior in Central Aortic Blood Pressure Reduction Compared with Perindopril/Amlodipine: A Randomized, Double-Blind Trial in Patients with Hypertension</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Ruilope</surname><given-names>Luis</given-names></name><address><email>ruilope@ad-hocbox.com</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Schaefer</surname><given-names>Angie</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><aff id="Aff1"><label/>Hypertension Unit, Hospital 12 de Octubre, 28041 Madrid, Spain </aff><aff id="Aff2"><label/>Department of Preventive Medicine and Public Health, Universidad Autonoma, Madrid, Spain </aff><aff id="Aff3"><label/>Daiichi Sankyo Europe GmbH, Zielstattstrasse 48, 81379 Munich, Germany </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>2</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>2</month><year>2015</year></pub-date><pub-date pub-type="ppub"><year>2015</year></pub-date><volume>32</volume><issue>2</issue><fpage>184</fpage><lpage>185</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2015</copyright-statement></permissions><related-article related-article-type="corrected-article" id="d30e91" ext-link-type="doi" xlink:href="10.1007/s12325-013-0076-6"/><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Healthcare 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Erratum to: Adv Ther (2013) 30(12):1086&#x02013;1099 DOI: 10.1007/s12325-013-0076-6</title><p>Some errors have been noted in the above-mentioned paper subsequent to publication and so the following corrections should be highlighted.</p><p>On page 1091 under the heading <bold><italic>Treatment Patterns</italic></bold>, the sentence &#x0201c;Overall, the mean duration of treatment was 152.6&#x000a0;days, and there were no major differences between the two treatment groups, including the duration of add-on HCTZ treatment&#x0201d; should read &#x0201c;Overall, the mean duration of treatment was 151.2&#x000a0;days, and there were no major differences between the two treatment groups, including the duration of add-on HCTZ treatment.&#x0201d; It should be clarified that 152.6&#x000a0;days was the mean duration of the double-blind treatment phase.</p><p>On page 1092 in <bold><italic>Fig.&#x000a0;3</italic></bold>, the <italic>p</italic> value for the FAS group should read <italic>p</italic>&#x000a0;=&#x000a0;0.0005, and not <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001.</p><p>On page 1095 under the heading <bold><italic>Safety/Tolerability</italic></bold>, the sentence &#x0201c;The most common adverse event was peripheral edema, which was reported in 17.8% of OLM/AML patients and 18.1% of PER/AML recipients&#x0201d; should read &#x0201c;The most common adverse event was peripheral edema, which was reported in 18.4% of OLM/AML patients and 17.8% of PER/AML recipients.&#x0201d;</p><p>On page 1095 in <bold><italic>Table&#x000a0;2</italic></bold>, the values in the row showing the frequencies of peripheral edema which are currently: 43 (17.8) in the OLM/AML column, 88 (18.1) in the PER/AML column, and 45 (18.4) in the total column; should read: 45 (18.4), 43 (17.8), and 88 (18.1), respectively.
</p></sec></body><back><fn-group><fn><p>The online version of the original article can be found under doi:10.1007/s12325-013-0076-6.</p></fn></fn-group><ack><title>Open Access</title><p>This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</p></ack></back></article>